8-K: Onconetix Faces Nasdaq Delisting Risk, Seeks Reverse Stock Split Approval

Onconetix is seeking shareholder approval for a reverse stock split to regain compliance with Nasdaq listing requirements after receiving notices regarding minimum bid price and stockholders' equity.

Summary

• Onconetix received a notice from Nasdaq on September 18, 2023, for not maintaining a minimum bid price of $1.00 per share.
• The company was granted an extension until September 16, 2024, to regain compliance with the bid price rule.
• On May 8, 2024, Onconetix received another notice for not meeting the minimum stockholders' equity requirement of $2,500,000.
• Nasdaq granted an extension until November 4, 2024, to regain compliance with the minimum stockholders' equity requirement.
• On July 30, 2024, Nasdaq determined that Onconetix's acquisition of Proteomedix AG constituted a change of control, requiring the company to meet initial listing criteria, including a minimum share price of $4.00.
• Onconetix is seeking shareholder approval for a reverse stock split in the range of 1-for-30 to 1-for-60 to increase its share price and meet Nasdaq requirements.
• Failure to comply with Nasdaq listing rules could result in delisting, which could negatively impact the company's stock liquidity, trading volume, and ability to raise capital.

Sentiment

Score: 3

Explanation: The document highlights significant challenges and risks related to Nasdaq listing compliance, indicating a negative outlook for the company's immediate future. The need for a reverse stock split and the potential for delisting are major concerns.

Positives

• Nasdaq has granted extensions for Onconetix to regain compliance with both the minimum bid price and stockholders' equity requirements.
• The company is actively seeking shareholder approval for a reverse stock split to address the share price issue.
• Onconetix has submitted a plan to Nasdaq to achieve and sustain compliance with listing rules.

Negatives

• Onconetix is currently not in compliance with multiple Nasdaq listing requirements, including minimum bid price and stockholders' equity.
• The company faces the risk of delisting from Nasdaq if it fails to regain compliance.
• Delisting could significantly reduce the liquidity and trading volume of the company's stock.
• The company's ability to raise capital may be diminished if delisted.

Risks

• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• Delisting could lead to reduced liquidity and trading volume of the company's stock.
• The company's ability to raise capital may be significantly diminished if delisted.
• The company may not be able to maintain analyst coverage if delisted.
• The reverse stock split may not be sufficient to regain compliance with Nasdaq listing rules.

Future Outlook

The company intends to release a portion of the Exchange Shares and the Conversion Shares from the Lock-Up Agreement and to effect the Reverse Stock Split to assist with satisfying applicable listing standards. The company is seeking shareholder approval for a reverse stock split to increase its share price and meet Nasdaq requirements.

Management Comments

• The Board believes that the failure of stockholders to approve the Reverse Stock Split Amendment could prevent the Company from complying with the Bid Price Rule and the Minimum Price Rule and could, among other risks, inhibit our ability to conduct capital raising activities.
• The Board's primary objective in asking for authority to effect a reverse split is to increase the per-share trading price of our Common Stock.

Industry Context

Many small-cap companies face challenges in maintaining Nasdaq listing compliance, especially regarding minimum share price and equity requirements. Reverse stock splits are a common strategy to address these issues, but they can also signal financial distress to the market.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain Nasdaq listing compliance, similar to Onconetix.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced delisting risks and have used reverse stock splits to regain compliance.
• The minimum stockholders' equity requirement of $2.5 million is a common hurdle for early-stage companies with limited revenue.
• The $4.00 minimum share price requirement after a change of control is a significant challenge for companies with low trading prices.

Stakeholder Impact

• Shareholders face the risk of significant losses if the company is delisted from Nasdaq.
• The company's ability to raise capital may be diminished, impacting future growth and operations.
• Employees may be affected by the company's financial instability and potential delisting.

Next Steps

• The company will seek shareholder approval for the reverse stock split at the Annual Meeting on September 5, 2024.
• The company must regain compliance with the minimum bid price rule by September 16, 2024.
• The company must regain compliance with the minimum stockholders' equity requirement by November 4, 2024.

Key Dates

Keywords

Nasdaq, delisting, reverse stock split, minimum bid price, stockholders' equity, compliance, listing rules, Proteomedix AG, change of control